Abstract: Objective This study aims to evaluate the efficacy and safety of anlotinib hydrochloride capsules in broad-stage small cell lung cancer(SCLC) patients that have received conventional secondary chemotherapy but still received no effective control, to study the efficacy and safety of this drug in broad-stage SCLC with conventional secondary chemotherapy but still no effective control. The primary outcome measures were time to no disease progression (PFS) and overall survival (OS). Methods A total of 13 extensive stage SCLC patients were selected who were reated at Fujian provincial hospital medical oncology from May 2018 to October 2018. Among these patients,progression or advers reactions after chemotherapy happened, with PS 0-2 points. the standard dose anlotinib treatment were given to them,and if patients suffered from intolerance advers reactions ,the dose of anlotinib can be reduced.The observation and analysis of anlotinib for second-line treatment of extensive SCLC were done for evaluation of drug efficacy and safety. The primary study endpoints were PFS and OS, and the secondary study endpoints were NSE level and safety of anlotinib,so as to provide the corresponding clinical basis for the promotion and application of anlotinib. Results After two to six cycles of treatment, we found that the mPFS of anlotinib was 5.2 months (95%CI 5.0~5.4); mOS 7.0 months. NSE decreased with anlotinib. Although the overall proportion of side effects reached 75%, only the proportion of grade 3/4 side effects was 5%. Conclusion Anlotinib is a treatment for SCLC that controls the development of the disease and has some efficacy; Third-line treatment of SCLC with anlotinib can significantly improve PFS and OS and has strong safety and good tolerability.

Key words: small-cell lung cancer, anlotinib, time for disease progress, effectiveness, adverse reaction